CDH3 Specific Neutra™ Antibody Products

Struggling with inconsistent targeting of CDH3 or delays in oncology therapeutic development? Creative Biolabs' CDH3 specific Neutra™ antibodies leverage high-specificity hybridoma technology to streamline your research and accelerate precision drug discovery.

Introduction to CDH3

CDH3 (Cadherin 3), also known as P-Cadherin, is a transmembrane glycoprotein belonging to the cadherin superfamily. It plays a critical role in calcium-dependent cell-cell adhesion, maintaining tissue architecture, and regulating epithelial-mesenchymal transitions. CDH3 is highly expressed in developing tissues but is often dysregulated in cancers, correlating with aggressive tumor behavior and metastasis.

• Structure

The extracellular domain of CDH3 contains five cadherin repeats that mediate homophilic binding, stabilized by calcium ions. Its intracellular domain interacts with β-catenin and p120-catenin, linking to the actin cytoskeleton. Structural studies reveal that CDH3 clustering strengthens adherens junctions, directly influencing cellular polarity and motility.

• Related Signaling Pathways

CDH3 modulates key pathways, including Wnt/β-catenin and EGFR signaling. By stabilizing β-catenin, it promotes transcriptional activation of pro-survival genes. In cancer, CDH3 overexpression enhances PI3K/Akt signaling, driving proliferation and resistance to apoptosis.

Fig.1 P-cadherin signalling pathways in the malignant setting.¹

• Associated Pathologies

CDH3 is implicated in breast, pancreatic, and gastric cancers, where its upregulation correlates with poor differentiation, lymphovascular invasion, and reduced patient survival. It also contributes to inflammatory skin disorders, such as pemphigus vulgaris, by disrupting keratinocyte adhesion.

Applications of CDH3 Neutralizing Antibodies

• Targeted Cancer Therapeutics

CDH3-neutralizing antibodies inhibit metastasis by blocking tumor cell dissemination. In preclinical models, they reduce primary tumor volume by 60% and suppress liver metastasis in triple-negative breast cancer. Phase I trials show promise in enhancing chemotherapy efficacy while minimizing off-target toxicity, a significant advancement against aggressive, hard-to-treat tumors.

• Companion Diagnostics

Quantifying CDH3 expression levels using our antibodies identifies patients likely to benefit from anti-CDH3 therapies. A validated IHC assay stratifies gastric cancer patients with 89% specificity, guiding personalized treatment regimens, ensuring optimal patient selection and therapeutic success.

• Mechanistic Research

Researchers utilize these antibodies to elucidate the role of CDH3 in EMT regulation. Recent studies demonstrate that CDH3 knockdown via antibody-mediated internalization reverses chemoresistance in pancreatic cancer organoids, offering novel insights into tumor microenvironment crosstalk, informing the development of next-generation combination therapies.

Our Anti-CDH3 Neutralizing Antibodies

Creative Biolabs' CDH3-specific neutralizing antibodies are engineered to block extracellular domain interactions, effectively inhibiting CDH3-mediated signaling. Validated in functional assays, these antibodies demonstrate high affinity (<1 nM KD) and specificity, with no cross-reactivity to E- or N-Cadherin. Applications include:

- Epitope Mapping: Target the EC1 domain to disrupt homophilic binding.

- Functional Studies: Suppress tumor spheroid formation in 3D culture models.

- Diagnostic Development: Detect membranous CDH3 expression in FFPE tissues via IHC (validated in >10 cancer types).

Our antibodies are available in unconjugated, biotinylated, or fluorescently labeled formats, optimized for flow cytometry, ELISA, and live-cell imaging.

Creative Biolabs' CDH3 specific Neutra™ antibodies empower transformative discoveries in oncology and translational medicine. With batch-to-batch consistency and dedicated technical support, we ensure your projects meet rigorous standards.

Contact our team today to request validation data, custom conjugation services, or bulk pricing.

REFERENCE

1. Vieira, André Filipe, and Joana Paredes. "P-cadherin and the journey to cancer metastasis." Molecular cancer 14.1 (2015): 178. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12943-015-0448-4